Compare · EIKN vs RVMD
EIKN vs RVMD
Side-by-side comparison of Eikon Therapeutics Inc. (EIKN) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EIKN and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $40.23B, about 83.5x EIKN ($481.8M).
- Over the past year, EIKN is down 40.2% and RVMD is up 407.1% - RVMD leads by 447.3 points.
- RVMD has been more active in the news (2 items in the past 4 weeks vs 1 for EIKN).
- RVMD has more recent analyst coverage (25 ratings vs 6 for EIKN).
- Company
- Eikon Therapeutics Inc.
- Revolution Medicines Inc.
- Price
- $8.86-7.61%
- $189.14+0.23%
- Market cap
- $481.8M
- $40.23B
- 1M return
- -8.00%
- +11.44%
- 1Y return
- -40.18%
- +407.15%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2026
- 2020
- News (4w)
- 1
- 2
- Recent ratings
- 6
- 25
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest EIKN
- Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress
- Eikon Therapeutics to Join the Russell 3000® Index
- SEC Form 3 filed by new insider Francisco Ma. Fatima
- Eikon Therapeutics Inc. filed SEC Form 8-K: Leadership Update
- Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors
- Eikon Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology
- Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology
- SEC Form SCHEDULE 13G filed by Eikon Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Eikon Therapeutics Inc.
Latest RVMD
- Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer
- European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process
- Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
- Director Patel Sushil exercised 2,955 shares at a strike of $37.54 and sold $1,048,967 worth of shares (5,580 units at $187.99) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 21,656 units (SEC Form 4)
- Chief Financial Officer Anders Jack exercised 20,000 shares at a strike of $18.56 and sold $3,366,604 worth of shares (20,000 units at $168.33) as part of a pre-agreed trading plan (SEC Form 4)
- Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
- Director Kim Lorence H. was granted 1,191 shares, increasing direct ownership by 2% to 74,281 units (SEC Form 4)
- Director Borisy Alexis was granted 1,191 shares, increasing direct ownership by 0.05% to 2,340,075 units (SEC Form 4)
- Director Anderson Elizabeth M was granted 1,191 shares, increasing direct ownership by 14% to 9,406 units (SEC Form 4)
- Director Horning Sandra was granted 1,191 shares, increasing direct ownership by 1% to 97,765 units (SEC Form 4)